Warner Robins

Researchers are evaluating ivonescimab as a first-line treatment for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. This phase 3 study compares ivonescimab to pembrolizumab, focusing on overall survival and progression-free survival to understand which treatment may better support patients with this condition. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab through intravenous injection. The study is double-blinded and multiregional, involving continuous treatment and monitoring for up to approximately 36 months. Both groups receive their assigned treatment regularly during this period, with careful observation of treatment responses and side effects. During the trial, participants will undergo evaluations including scans to measure tumor size, laboratory tests, and assessments of adverse events. Researchers will track overall survival, progression-free survival, response rates, disease control, and duration of response. Safety monitoring will continue for up to 24 months after the last dose. The total study period extends until June 2029, allowing long-term data collection on treatment effects and safety.

Researchers are comparing two devices used to widen the upper jaw in children aged 6 to 11 years who need maxillary expansion due to conditions such as malocclusions, narrow maxilla, narrow maxillary arch, or crowding. The study aims to evaluate the amount of palate expansion achieved and the overall experience of using the Invisalign Palatal Expander versus the Hyrax expander. Participants will be randomly assigned to use either the Invisalign Palatal Expander, a removable device that is replaced to achieve up to 0.25 mm expansion per device, or the Hyrax Expander, a banded device fixed in the mouth where a screw is turned to obtain 0.25 mm expansion per turn. The study duration is approximately four months from enrollment to completion. During the study, participants will be monitored to measure the width of their palate after expansion. The study involves regular assessments to track changes in palate width and overall device experience. The total participation time is about four months, during which safety and effectiveness will be evaluated under medical supervision.

Researchers are evaluating a new approach for managing atrial fibrillation AF in adults aged 22 to 85 who have a history of paroxysmal or persistent AF with low-to-moderate stroke risk. The trial compares the current standard care of continuous use of direct oral anticoagulants DOAC with a time-limited DOAC use guided by an AF-sensing Smart Watch AFSW. This phase 3, multicenter, randomized clinical trial aims to assess if the AFSW-guided DOAC therapy is as effective as continuous therapy in preventing stroke, systemic embolism, or death. Participants are randomly assigned to either the experimental group, where they receive an AFSW linked to their Apple Watch and take DOAC for 30 days following an AF episode detected by the watch, or the control group, who continue their prescribed continuous DOAC regimen without the AFSW guidance. The AFSW passively monitors heart rhythm and alerts both the participant and the study center if a significant AF event occurs. Both groups use the REACT-AF app for study follow-up, but only the experimental group receives the AFSW device with the detection algorithm. During the study, participants will be monitored for up to 60 months with assessments including heart rhythm tracking, clinical evaluations, and safety monitoring. Researchers will measure the occurrence of ischemic stroke, systemic embolism, all-cause mortality, and major bleeding events to compare the two treatment approaches. Participants adherence to DOAC therapy and use of the smart watch device will be tracked, and the study will be conducted across multiple sites including academic and private practices.